Molecular pathology of parathyroid tumors

Trends in Endocrinology and Metabolism

Volumn 12, Issue 2, 2001, Pages 53-58

  Carling, Tobias ^a,b  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL RECEPTOR; CYCLIN D1;

ADENOMA; GENETIC PREDISPOSITION; GENETICS; HUMAN; HYPERPLASIA; MULTIPLE ENDOCRINE NEOPLASIA; MUTATION; PARATHYROID GLAND; PARATHYROID TUMOR; PATHOLOGY; REVIEW;

ADENOMA; CYCLIN D1; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERPLASIA; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; MUTATION; PARATHYROID GLANDS; PARATHYROID NEOPLASMS; RECEPTORS, CALCITRIOL;

EID: 0035286349     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-2760(00)00345-3     Document Type: Review

References (61)

1. Lundgren, E. et al. (1997) Population-based health screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women. Surgery 121, 287-294
2. Chattopadhyay N. et al. (1996) The calciumsensing receptor: a window into the physiology and pathophysiology of mineral ion metabolism. Endocr. Rev. 17, 289-307
3. Haussler, M. et al. (1998) The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J. Bone Miner. Res. 13, 325-349
4. Silver, J. et al. (1997) Regulation of parathyroid cell proliferation. Curr. Opin. Nephrol. Hypertens. 6, 321-326
5. Fukuda, N. et al. (1993) Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J. Clin. Invest. 92, 1436-1443
6. Carling, T. et al. (2000) Reduced vitamin D receptor mRN A levels in parathyroid glands of primary and secondary hyperparathyroidism. J. Clin. Endocrinol. Metab. 85, 2000-2003
7. Ho, C. et al. (1995) Amouse model of human familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Nat. Genet. 11, 389-394
8. Brown, E. (1997) Mutations in the calciumsensing receptor and their clinical implications. Horm. Res. 48, 199-208
9. LeBoff, M.S. et al. (1985) Regulation of parathyroid hormone release and cytosolic calcium by extracellular calcium in dispersed and cultured bovine and pathological human parathyroid cells. J. Clin. Invest. 75, 49-57
10. 2+-sensing receptor in primary and uremic secondary hyperparathyroidism. J. Clin. Endocrinol. Metab. 81, 1598-1606
11. Carling, T. et al. (1995) Vitamin D receptor genotypes in primary hyperparathyroidism. Nat. Med. 1, 1309-1311
12. Carling, T. et al. (1997) Vitamin D receptor alleles b, a and T: risk factors for sporadic primary hyperparathyroidism (HPT) but not HPT of uremia or MEN 1. Biochem. Biophys. Res. Commun. 231, 329-332
13. Carling,T. et al. (1997) VitaminD receptor polymorphisms correlate to parathyroid cell function in primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 82, 1772-1775
14. Carling, T. et al. (1998) Vitamin D receptor (VDR) and parathyroid hormone mRN A levels correspond to polymorphic VDR alleles in human parathyroid tumors. J. Clin. Endocrinol. Metab. 83, 2255-2259
15. Mitlak, B. et al. (1996) Association of a polymorphic allele of the vitamin D receptor gene with primary hyperparathyroidism in men and women. J. Bone Miner Res. 11, 5212
16. Kaun, M. et al. (1997) Vitamin D receptor genotypes in patients with primary and secondary hyperparathyroidism. Langenbecks Arch. Chir Suppl. Kongressbd 114, 773-775
17. Nagasaka, S. et al. (1996) Vitamin D receptors and hyperparathyroidism. Nat. Med. 2, 834
18. Kobayashi, T. et al. (1998) Vitamin D receptor genotype is associated with cortical bone loss in Japanese patients with primary hyperparathyroidism. Endocr J. 45, 123-125
19. Beavan, S. et al. (1996) Differences in the vitamin D receptor genotype and geographical variation in osteoporosis. Lancet 348, 136-137
20. Ingles, S. et al. (1997) Strength of linkage disequilibrium between two vitamin D receptor markers in five ethnic groups: implications for association studies. Cancer Epidemiol. Biomarkers Prev. 6, 93-98
21. Arnold, A. etal. (1988) Monoclonality and abnormal parathyroid hormone genes in parathyroid adenomas. New Engl. J. Med. 318, 658-662
22. Arnold, A. (1994) Molecular basis of primary hyperparathyroidism. In The Parathyroids (Bilezikian JP. et al. eds), pp. 407-421, Raven Press
23. Arnold, A. et al. (1995) Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia. J. Clin. Invest. 95, 2047-2053
24. Cryns, V.L. et al. (1994) Loss of the retinoblastoma tumor-suppressor gene in parathyroid carcinoma. New Engl. J. Med. 330, 757-761
25. Arnold, A. et al. (1989) Molecular cloning and chromosomal mapping of DNA rearranged with the parathyroid hormone gene in parathyroid adenoma. J. Clin. Invest. 83, 2034-2040
26. Motokura, T. et al. (1991) Anovel cyclin encoded by a bcl1-linked candidate oncogene. Nature 350, 512-515
27. Hosokawa, Y. and Arnold, A. (1996) Cyclin D1/PRAD1 as a central target in oncogenesis. J. Lab. Clin. Med 127, 246-252
28. Hsi, E. et al. (1996) Cyclin D 1/PRAD1 expression in parathyroid adenomas: an immunohistochemical study J. Clin. Endocrinol. Metab. 81, 1736-1739
29. Hinds, P. et al. (1994) Function of a human cyclin gene as an oncogene. Proc. Natl. Acad. Sci. U. S. A. 91, 709-713
30. Palanisamy, N. et al. (1998) Novel chromosomal abnormalities identified by comparative genomic hybridization in parathyroid adenomas. J. Clin. Endocrinol. Metab. 83, 1766-1770
31. Heppner, C. et al. (1997) Somatic mutations of the MEN1 gene in parathyroid tumours. Nat. Genet. 16, 375-378
32. Carling, T. et al. (1998) Parathyroid MEN1 gene mutations in relation to clinical characteristics of non-familial primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 83, 2960-2963
33. Farnebo, F. et al. (1998) Alterations of the MEN1 gene in sporadic parathyroid tumors. J. Clin. Endocrinol. Metab. 83, 2627-2630
34. Tahara, H. et al. (1996) Genomic localization of novel candidate tumor suppressor gene loci in human parathyroid adenomas. Cancer Res. 56, 599-605
35. Tahara, H. et al. (1996) Loss of chromosome arm 9p DNA and analysis of the p!6 and p15 cyclindependent kinase inhibitor genes in human parathyroid adenomas. J. Clin. Endocrinol. Metab. 81, 3663-3667
36. Tahara, H. et al. (1997) Parathyroid tumor suppressor on 1p : analysis of the p 18 cyclindependent kinase inhibitor gene as a candidate. J. Bone Miner. Res. 12, 1330-1334
37. Carling, T et al. (1999) Expression and sequence analysis oiradSl: a candidate tumor suppressor gene on chromosome 15q in a region frequently deleted in parathyroid tumors. Clin. Endocrinol. 51, 403-408
38. Carling, T. et al. (1999) Analysis of the RAD54 gene on chromosome 1p as a potential tumorsuppressor gene in parathyroid adenomas. Int. J. Cancer 83, 80-82
39. Franklin, D. et al. (2000) Functional collaboration between different cyclin-dependent kinase inhibitors suppresses tumor growth with distinct tissue specificity. Mol. Cell. Biol. 20, 6147-6158
40. +/- mice. Proc. Natl. Acad. Sci. U. S. A. 96, 3916-3921
41. Dotzenrath, C. et al. (1996) Allelic loss of the retinoblastoma tumor suppressor gene: a marker for aggressive parathyroid tumors? J. Clin. Endocrinol. Metab. 81, 3194-3196
42. Pearce, S. et al. (1996) Loss of heterozygosity studies at the retinoblastoma and breast cancer susceptibility (BRCA2) loci in pituitary, parathyroid, pancreatic and carcinoid tumors. Clin. Endocrinol. 45, 195-200
43. Agarwal, S. et al. (1998) Comparative genomic hybridization analysis of human parathyroid tumors. Cancer Genet. Cytogenet. 106, 30-36
44. Skogseid, B. et al. (1994) Multiple endocrine neoplasia type 1: clinical features and screening. Endocrinol. Metab. Clin. North Am. 23, 1-18
45. Chandrasekharappa, S. et al. (1997) Positional cloning of the gene for multiple endocrine neoplasia type 1. Science 276, 404-407
46. Guru, S. et al. (1998) Menin, the product of the MEN1 gene, is a nuclear protein. Proc. Natl. Acad. Sci. U. S. A. 95, 1630-1634
47. Agarwal, S. et al. (1999) Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription. Cell96, 143-152
48. Kraimps, J. et al. (1996) Primary hyperparathyroidism in multiple endocrine neoplasia type IIa: retrospective French multicentric study. World J. Surg. 20, 808-812
49. Mulligan, L. and Ponder, B. (1995) Genetic basis of endocrine disease: multiple endocrine neoplasia type 2. J. Clin. Endocrinol. Metab. 80, 1989-1995
50. Szabo, J. et al. (1995) Hereditary hyperparathyroidism-jaw tumor syndrome: the endocrine tumor gene HRPT2 maps to chromosome Iq21-q31. Am. J. Hum. Genet. 56, 944-950
51. Teh, B. et al. (1996) Autosomal dominant primary hyperparathyroidism and jaw tumor syndrome associated with renal hamartomas and cystic kidney disease: linkage to Iq21-q32 and loss of the wild type allele in renal hamartomas. J. Clin. Endocrinol. Metab. 81, 4204-4211
52. Wassif, W. et al. (1999) Genetic studies of a family with hereditary hyperparathyroidism-jaw tumour syndrome. Clin. Endocrinol. 50, 191-196
53. Haven, C. et al. (2000) Agenotypic and histopathological study of a large Dutch kindred with hyperparathyroidism-jaw tumor syndrome. J. Clin. Endocrinol. Metab. 85, 1449-1454
54. Huang, S. et al. (1997) Familial hyperparathyroidism without multiple endocrine neoplasia. World J. Surg. 1, 22-28
55. Teh, B. et al. (1998) Familial isolated hyperparathyroidism maps to the hyperparathyroidism-jaw tumor locus in Iq21-q32 in a subset of families. J. Clin. Endocrinol. Metab. 83, 2114-2120
56. Teh, B. et al. (1998) A family with isolated hyperparathyroidism segregating a missense MEN1 mutation and showing loss of the wild-type alleles in the parathyroid tumors. Am. J. Hum. Genet 63, 1544-1549
57. Kassem, M. et al. (2000) Familial isolated hyperparathyroidism as a variant of multiple endocrine neoplasia type 1 in a large Danish pedigree. J. Clin. Endocrinol. Metab. 85, 165-167
58. Pollak, M.R. et al. (1993) Mutations in the human Ca(2+)-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell 75, 1297-1303
59. Heath, H., III et al. (1993) Genetic linkage analysis in familial benign (hypocalciuric) hypercalcemia: evidence for locus heterogeneity. Am. J. Hum. Genet. 53, 193-200
60. Lloyd, S. et al. (1999) Localization of familial benign hypercalcemia, Oklahoma variant (FBHOk), to chromosome 19q13. Am. J. Hum. Genet 64, 189-195
61. Carling, T et al. (2000) Familial hypercalcemia and hypercalciuria caused by a novel mutation in the cytoplasmic tail of the calcium receptor. J. Clin. Endocrinol. Metab. 85, 2042-2047